On the bright sideIf, by chance, AbbVie starts promoting a 1067 product at the same time, early next year, when GlycoProtemim hits the market, it could get interesting.
It will likely be a painful 2024 for SBM's downtrodden shareholders, but what if...................?
We have held our noses this long, what's another year, if they actually pull this off? And who really wants to sell at the all-time bottom? Not me, that's for sure.
GLTA, we deserve it.